DEVELOPMENT AND CORRELATION BETWEEN IN VITRO DRUG RELEASE AND IN VITRO PERMEATION OF THERMALLY TRIGGERED MUCOADHESIVE IN SITU NASAL GEL OF REPAGLINIDE PVP K30 COMPLEX

Authors

  • Kamla Pathak Pharmacy College Saifai, Uttar Pradesh University of Medical Sciences, Etawah 206130, Uttar Pradesh, India
  • Anil Kumar Department of Pharmaceutics, Rajiv Academy for Pharmacy, Mathura 281001, Uttar Pradesh, India
  • Ekta Yadav Department of Pharmaceutics, Rajiv Academy for Pharmacy, Mathura 281001, Uttar Pradesh, India

Abstract

The aim of the investigation was to develop and evaluate thermoreversible in situ nasal gel formulations of repaglinide (REP) and to establish correlation between its in vitro release and ex vivo permeation profiles. The solubility of REP was enhanced by preparing solid dispersions (SDs) with hydrophilic carriers (PVP K30/ PEG 6000/ poloxamer 188) in different weight ratios. REP: PVP K30 (1:5) was selected as the optimized SD as it showed highest enhancement in solubility (405%). The optimized SD was characterized by SEM and DSC and incorporated into a blend of thermoreversible and mucoadhesive polymers (poloxamer 407 and carbopol 934 P) by cold technique to form in situ gels (F1-F6). The prepared in-situ gels were evaluated for various pharmacotechnical features and the formulation F3 exhibited least gelling time of 6.1± 0.20, good mucoadhesive property to ensure sufficient residence time at the site of application and a %CDR of 82.25%. The ex vivo permeation characteristics across goat mucosa can be summarized as CDP of 78.7%, flux = 6.80 mg/cm2/h; permeability coefficient of 2.02 mg/h and zero order kinetics. On correlating the CDR profile of F3 with that of its CDP profile, a R2 value of 0.991 (slope= 0.921) was observed. The value of slope approximating one, suggested that almost entire amount of drug released from F3 was capable of permeating across the nasal mucosa, ex-vivo indicating that in-situ nasal gels of REP for systemic action can be successfully developed for the management non-insulin dependent type-II diabetes mellitus.

Keywords:

Solid dispersion, nasal in-situ gel, in vitro release, permeation characteristics, correlation

DOI

https://doi.org/10.25004/IJPSDR.2019.110104

References

1. Illum L. Nasal drug delivery: new developments and strategies. Drug Discovery Today 2002; 23(7): 1184-9.
2. Hirlekar RS. Momin AM. Advances in Drug Delivery from Nose to Brain: An Overview. Curr Drug Ther. 2018; 13:4-24.
3. Chien YW. Nasal drug delivery and delivery system In: Novel drug delivery systems. 2nd ed. Marcel Dekker Inc; 1992. p. 229-268.
4. Chatterji B. Nose to Brain Delivery: Recent update. J Formul Sci Bioavail. 2017;1: 105-111.
5. Huang Y, Dai W-G. Fundamental aspects of solid dispersion technology for poorly water-soluble drugs. Acta Pharm Sinica B. 2014;4: 18-25.
6. Sean C S, Martindale: The complete drug reference. 36th ed. Pharmaceutical press; 2009. p. 457-458.
7. El-Houssieny BM, Wahman L, Arafa NM. Bioavailability and biological activity of liquisolid compact formula of repaglinide and its effect on glucose tolerance in rabbits. Biosci Trends. 2010; 4:17-24.
8. Tripathi KD. Essentials of Pharmacology. 6th ed. Jaypee brother’s medical publishers; 2007. p. 266-269.
9. Purvis T, Mattucci EM, Crisp TM, et al. Rapidly dissolving repaglinide powders produced by the ultra-rapid freezing process. AAPS PharmSciTech. 2007; 8(2):E52-E60.
10. Dhanalekshmi UM, Poovia G, Reddy PN, In vitro observation of repaglinide engineered polymeric nanoparticles. Digest J Nanomat Biostruct. 2012; 7:1-18.
11. Rao MEB, Swain S, Patra CN, et al., Development and in vitro evaluation of floating multiparticulate system of repaglinide. FABAD J Pharm Sci. 2011; 36:75-92.
12. Joshi J, Bhakuni L, Kumar S. Formulation and evaluation of solid matrix tablets of repaglinide. Der Pharmacia Sinica. 2012; 3(5):598-603.
13. Schmolka IR. Artificial skin.1.Preparation and properties of pluronic F-127 gels for the treatment of burns. J Biomed Mater Res. 1972; 6: 571-582.
14. Miller SC, Donovan MD. Effect of poloxamer 407 gel on the miotic activity of pilocarpine nitrate in rabbits. Int J Pharm.1982; 12: 147-152.
15. Choi HG, Jung JH, Ryu JM. Development of in situ gelling and mucoadhesive acetaminophen liquid suppository. Int J Pharm. 1998; 165: 33-44.
16. Garg A, Garg S, Khar RK. Measurement of bioadhesive strength of mucoadhesive buccal tablet: design of an in-vitro assembly. Indian Drugs. 1992; 30: 152-155.
17. Moffat AC, Osselton MD, Widdop B. (Eds.) Clarke's Analysis of Drugs and Poisons (3rd Ed., 2004), Pharmaceutical Press, London, UK, Vol. 1.
18. Akiladevi D, Shanmugapandiyan P, Jebasingh D, et al. Preparation and evaluation of paracetamol by solid dispersion technique. Int J Pharm Pharm Sci. 2011; 3:188-191.
19. Huang Y, Dai W-G, Fundamental aspects of solid dispersion technology for poorly water soluble drugs. Acta Pharm Sinica B. 2014; 4:18-25.
20. Charlton S, Jones NS, Davis SS, et al. Distribution and clearance of bioadhesive formulations from olfactory region in man: effect of polymer type and nasal delivery device. Eur J Pharm Sci. 2007; 30: 295-302.
21. Patel M, Thakkar H, Kasture PV. Preparation and evaluation of thermoreversible formulations of flurazine hydrochloride for nasal delivery. Int J Pharm Pharm Sci. 2010; 2: 116-120.
22. Zhou M, Donovan MD. Intranasal mucociliary clearance of putative bioadhesive polymers gels. Int J Pharm 1996; 135: 115-125.
23. Majithiya RJ, Ghosh PK, Umrethia ML, et al. Thermoreversible mucoadhesive gel for nasal delivery of sumatriptan. AAPS PharmSciTech 2006; 7(3): E1-E7.
24. Kabanov AV, Batrakova EV, Alakhov VU. Pluronic block copolymers as novel polymer therapeutics for drug and gene deliver. J Control Release. 2002; 82: 189-212.
25. Bromberg LE, Ron ES. Protein and peptide release from temperature-responsive gels and thermogelling polymer matrices. Adv Drug Deliv Rev. 1998; 31: 197-221.
26. Mahajan HS, Shah SK, Surana SJ. In-situ gelling system based on thiolated gellan gum as new carrier for nasal administration of dimenhydrinate. Int J Pharm Sci Nanotech. 2009; 2: 544-550.
27. Kunisawa J, Okudaira A, Tsutusmi Y. Characterization of mucoadhesive microspheres for the induction of mucosal and systemic immune responses. Vaccine. 2000; 19:589-594.
28. He C, Kim SW, Lee DS. In situ gelling stimuli-sensitive block copolymer hydrogels for drug delivery. J Control Release. 2008; 127:189-207.
29. Mortensen K, Pedersen JS. Structural study on the micelle formation of poly (ethylene oxide)-poly (propylene oxide)-poly (ethylene oxide) triblock copolymer in aqueous solution. Macromolecules.1993; 26: 805-812.
30. Riccia EJ, Lunardi LO, Nanclares DMA, et al. Sustained release of lidocaine from poloxamer 407 gels. Int J Pharm. 2005; 288: 235-244.

Published

20-01-2019
Statistics
Abstract Display: 477
PDF Downloads: 736
Dimension Badge

How to Cite

“DEVELOPMENT AND CORRELATION BETWEEN IN VITRO DRUG RELEASE AND IN VITRO PERMEATION OF THERMALLY TRIGGERED MUCOADHESIVE IN SITU NASAL GEL OF REPAGLINIDE PVP K30 COMPLEX”. International Journal of Pharmaceutical Sciences and Drug Research, vol. 11, no. 1, Jan. 2019, pp. 22-30, https://doi.org/10.25004/IJPSDR.2019.110104.

Issue

Volume 11, Issue 1, 2019

Section

Research Article

How to Cite

“DEVELOPMENT AND CORRELATION BETWEEN IN VITRO DRUG RELEASE AND IN VITRO PERMEATION OF THERMALLY TRIGGERED MUCOADHESIVE IN SITU NASAL GEL OF REPAGLINIDE PVP K30 COMPLEX”. International Journal of Pharmaceutical Sciences and Drug Research, vol. 11, no. 1, Jan. 2019, pp. 22-30, https://doi.org/10.25004/IJPSDR.2019.110104.